Pancreatic Cancer Research

ResearcherUniversität UlmActive in the last 2 years

Yongsu Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3631-754X; OpenAlex author ID A5100443134, A5134059495. Sources: OpenAlex.

Their work

Papers
25 (first author 7, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers · 2026: 6 papers

Papers 25

  1. Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis. Co-author DOI 10.1002/advs.75216↗
  2. Exosomal miR-4644 Targets SPRY3 to Promote Proliferation and Invasion of Pancreatic Cancer. Co-author DOI 10.1002/cam4.72000↗
  3. SGLT2 inhibition induces autophagic flux blockade and sensitizes pancreatic cancer to EGFR-targeted therapy. Co-author DOI 10.1007/s13402-026-01256-9↗
  4. A deep learning pathomic signature predicts survival and recurrence in pancreatic ductal adenocarcinoma independent of CA19-9. Last author DOI 10.1016/j.canlet.2026.218452↗
  5. Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy. Co-author DOI 10.1016/j.isci.2026.116029↗
  6. Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics. First author DOI 10.1136/gutjnl-2025-335683↗
  7. Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single-center retrospective study in … First author DOI 10.1002/acm2.70092↗
  8. Tumor-derived exosomes: Unravelling the pathogenesis of pancreatic cancer with liver metastases and exploring the potential for clinical translation. Co-author DOI 10.1016/j.canlet.2024.217403↗
  9. Multi-omics analysis of polyamine metabolism implicates NT5E/CD73 in the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217887↗
  10. Prognostic implications and characterization of tumor-associated tertiary lymphoid structures genes in pancreatic cancer. First author DOI 10.1186/s12967-025-06152-8↗
  11. Current status and future prospects of cancer-derived immunoglobulins in pancreatic cancer. Co-author DOI 10.7150/jca.109497↗
  12. Hypoxia-induced epigenetic regulation of miR-485-3p promotes stemness and chemoresistance in pancreatic ductal adenocarcinoma via SLC7A11-mediated ferroptosis. Co-author DOI 10.1038/s41420-024-02035-x↗
  13. Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis. Co-author DOI 10.3389/fonc.2024.1327280↗
  14. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis. Co-author DOI 10.1007/s10238-023-01112-2↗
  15. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy. First author DOI 10.1016/j.canlet.2023.216421↗
  16. Predictive Model of Early Death of Resectable Pancreatic Ductal Adenocarcinoma After Curative Resection: A SEER-Based Study. First author DOI 10.1177/10732748221084853↗
  17. Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/genes13101760↗
  18. Metabolic detection and systems analyses of pancreatic ductal adenocarcinoma through machine learning, lipidomics, and multi-omics. Co-author DOI 10.1126/sciadv.abh2724↗
  19. Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practic… First author DOI 10.21037/hbsn-20-383↗
  20. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center anal… Co-author DOI 10.21147/j.issn.1000-9604.2021.04.03↗
  21. Spatial heterogeneity in epithelial to mesenchymal transition properties of circulating tumor cells associated with distant recurrence in pancreatic cancer pat… First author DOI 10.21037/atm-20-782↗
  22. LncRNA H19-Derived miR-675-3p Promotes Epithelial-Mesenchymal Transition and Stemness in Human Pancreatic Cancer Cells by targeting the STAT3 Pathway. Co-author DOI 10.7150/jca.44833↗
  23. Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagi… Co-author DOI 10.1002/ijc.31211↗
  24. Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo. Co-author DOI 10.3390/ijms18040716↗
  25. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Co-author DOI 10.1016/j.ejca.2014.05.017↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaodong Tian · 16 shared papers, 2014–2026 · strength 3.21
  2. Yinmo Yang · 14 shared papers, 2018–2026 · strength 2.82
  3. Yinmo Yang · 6 shared papers, 2014–2026 · strength 1.03
  4. Xiaodong Tian · 5 shared papers, 2018–2025 · strength 0.94
  5. Kai Chen · 4 shared papers, 2022–2026 · strength 0.82
  6. Yiran Chen · 4 shared papers, 2021–2025 · strength 0.78
  7. Enkui Zhang · 3 shared papers, 2025–2026 · strength 0.73
  8. Weikang Liu · 4 shared papers, 2021–2024 · strength 0.68
  9. Yinmo Yang · 3 shared papers, 2024–2026 · strength 0.67
  10. Yingjin Wang · 3 shared papers, 2023–2026 · strength 0.66
  11. Xiangyu Chu · 2 shared papers, 2025–2026 · strength 0.58
  12. Xiaodong Tian · 2 shared papers, 2026 · strength 0.57
  13. Dongqi Li · 2 shared papers, 2024–2025 · strength 0.48
  14. Long Di · 2 shared papers, 2023 · strength 0.38
  15. Zhengkui Zhang · 3 shared papers, 2018–2021 · strength 0.35
  16. Zichen Pan · 1 shared paper, 2026 · strength 0.33
  17. Dongqi Li · 1 shared paper, 2026 · strength 0.30
  18. Yuxin Wang · 1 shared paper, 2026 · strength 0.30
  19. Xiu Rong Dong · 2 shared papers, 2020–2021 · strength 0.27
  20. Xiaohang Zhao · 2 shared papers, 2020–2021 · strength 0.27
  21. Xiaojuan Du · 1 shared paper, 2025 · strength 0.27
  22. Robert A. Anders · 1 shared paper, 2026 · strength 0.26
  23. Heng‐Chung Kung · 1 shared paper, 2026 · strength 0.26
  24. Pengfei Wu · 1 shared paper, 2026 · strength 0.26
  25. Jacquelyn W. Zimmerman · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.